What a medicine licence means

The MHRA licenses medicines for the UK. Product information must be checked for the exact medicine, formulation, strength, age group and use. A US FDA approval does not establish a UK licence or UK prescribing instructions.

Since 1 January 2025, the Windsor Framework arrangements provide for MHRA UK-wide authorisations, including Northern Ireland. Earlier PLGB licence numbers may remain on products whose territorial coverage became UK-wide. NI-only authorisations can also remain, so a licence prefix alone does not establish the full current position. Product-level records still matter.

UK-wide medicines arrangements cover the United Kingdom. They do not make a UK licence applicable to the Republic of Ireland.

Reading the product information

The Summary of Product Characteristics, often called an SmPC or SPC, sets out the product's authorised conditions of use for health professionals. The Patient Information Leaflet explains safe use for the person taking it. Check the actual product, not just the active ingredient: different brands, release mechanisms, strengths and routes can have different instructions.

A listed tablet strength or liquid concentration is not a recommended daily dose. Dosing, titration, age restrictions and monitoring need the relevant product and clinical context. Neither an overseas label nor this overview replaces those checks.

Licensing, recommendations and access

Licensing concerns the authorised product and its uses. Clinical guidance considers when a treatment is appropriate. Health technology assessments and commissioning decisions consider NHS access and resources. Local services also need the staff and facilities to provide treatment. These stages should not be described as interchangeable.

An off-label use falls outside that product’s authorised terms. It needs its own evidence and clinical context; mention in an article does not mean it is routinely recommended, funded or suitable for an individual.

Off-label and unlicensed are not synonyms. Off-label describes a licensed product used outside its authorised terms, such as a different indication or age group; an unlicensed product has no applicable marketing authorisation. A clinician may sometimes justify either, but must consider evidence, risks, communication, monitoring and follow-up. A guideline recommendation does not itself amend the product licence.

England

NICE is a key source of national treatment guidance and technology assessments for England. Read the exact guidance, population, indication and conditions attached to a recommendation; a broad reference to NICE is not evidence for every use of a medicine.

Clinical guidelines and technology appraisal guidance are different products. The funding duties attached to a positive technology appraisal concern its specified conditions; they should not be attached indiscriminately to every NICE clinical recommendation.

Scotland

SIGN develops evidence-based clinical guidance for NHS Scotland. The Scottish Medicines Consortium assesses new medicines for NHS Scotland, including clinical and economic evidence. Its advice and local arrangements should be checked for the exact indication. A UK licence does not by itself establish routine NHS Scotland access.

SMC advice may accept a medicine, restrict its use to a defined group, accept it temporarily pending further evidence, or not recommend it. NHS boards publish local formularies and have individual-request processes; a negative or absent routine recommendation is not the same as a UK licensing ban.

Wales

NICE guidelines and quality standards are available for use in Wales under Welsh arrangements and legislation. Welsh Government distinguishes non-mandatory guidelines and quality standards from technology appraisal guidance, which carries separate access requirements. The All Wales Medicines Strategy Group also has a role in medicine assessment.

Northern Ireland

Northern Ireland has its own Department of Health processes for considering and endorsing NICE guidance. The clinical-guideline process was updated with arrangements effective from 1 July 2026. Check the relevant endorsement and HSC service pathway rather than assuming publication by NICE means identical implementation across the UK.

Safety warnings and additional monitoring

UK safety information comes from product information and MHRA safety communications. A black inverted triangle identifies additional monitoring: it asks for particularly close reporting of suspected adverse reactions and does not by itself mean a medicine is unsafe. It is not a UK version of an FDA boxed warning.

Patients and professionals can report suspected medicine reactions through the MHRA Yellow Card scheme; proof that the medicine caused the reaction is not required. Reporting helps identify safety signals but does not replace medical assessment or urgent care for a serious reaction.

Prescribing and continuing responsibility

A specialist recommendation does not automatically transfer prescribing to a GP. Shared care requires agreement between the clinicians and the patient, clear communication and an agreed monitoring plan. The prescriber remains responsible for deciding whether a prescription is appropriate and safe. Ask who will issue prescriptions, arrange tests and review side effects before a transfer of care.

Sources and References

  1. UK-wide licensing for human medicines

    Scope: United Kingdom, including Northern Ireland; authorisation-specific exceptions.

  2. Introducing new medicines in the NHS in the UK - pathway

    Scope: United Kingdom; nation-specific access routes.

  3. Off-label or unlicensed use of medicines: prescribers’ responsibilities

    Scope: United Kingdom.

  4. Scottish Intercollegiate Guidelines Network (SIGN) role in NHS guidelines: FOI release

    Scope: Scotland.

  5. How we decide

    Scope: Scotland.

  6. National Institute for Health and Care Excellence (NICE) guidelines

    Scope: Wales.

  7. NICE Clinical Guidelines

    Scope: Northern Ireland.

  8. Find product information about medicines

    Scope: United Kingdom.

  9. The Yellow Card scheme: guidance for healthcare professionals, patients and the public

    Scope: United Kingdom medicine safety reporting.

  10. Shared care — professional standards

    Scope: United Kingdom.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top